Objectives. The objective of this study was to assess the effect that triple therapy (anticoagulation plus CS plus plasma exchange and/or IVIGs) has on the mortality risk of patients with catastrophic APS (CAPS) included in the CAPS Registry.
Introduction
The combination of anticoagulation plus CS plus plasma exchange and/or IVIG, the so-called triple therapy, has been claimed for a long time as the best treatment for catastrophic APS (CAPS) [1, 2] . Despite the fact that strong biological reasons have been proposed to support the beneficial effect of triple therapy in patients with this devastating condition [3] , the rarity of its presentation has precluded conducting clinical trials. Moreover, the analysis of epidemiologic data has provided contradictory results [2, 4] . To date, the best available evidence comes from a study that showed a better prognosis of those patients diagnosed after 2001, when a consensus agreement proposing the use of triple therapy to treat patients with CAPS was published [5] .
To evaluate the clinical benefit of triple therapy in the treatment of CAPS, we conducted a retrospective cohort study comparing the mortality rate among patients who received triple therapy treatment (i.e. anticoagulation, CS and plasma exchange and/or IVIG) to those who were treated with other therapeutic combination.
Methods

Patients
The study is based on the data of patients included in the CAPS Registry. This is a database that contains data for patients with CAPS from April 1992 (when CAPS was first described) to December 2015. Patients included in the CAPS Registry had either been reported to the CAPS Registry coordinators or their case had been published in the literature. Data are standardized by anonymized data forms fulfilled by their treating physicians. Received cases are checked by the CAPS Registry data manager with the database and eventually with the sending physician to rule out duplicates. Published case reports are identified through a periodic systematic review of all cases available in MEDLINE in any language using the following MeSH terms: CAPS, or catastrophic APS. Additionally, references were reviewed to identify further cases. All patients had to meet current accepted classification criteria of CAPS [1, 6] .
The study was designed by the authors and approved by the clinic investigation ethics committee of the Hospital Clinic of Barcelona, which waived the requirement for individual informed consent.
Demographic, clinical and immunological features of each patients with CAPS were registered. CAPS episodes were classified in three groups according to the treatment received: those that received the so-called triple therapy (combination of anticoagulation plus CS plus plasma exchange and/or IVIG); those that received any other combination of these treatments; and those that received none of these treatments. The study endpoint was survival as reported by their treating physician.
Statistical analysis
Descriptive analysis of demographical, clinical and immunological variables of the cases was performed. Numerical variables are described with mean (S.D.). For categorical variables, sample size and percentage are presented.
Survival was the dependent variable in all analysis. A single patient could have suffered multiple episodes of CAPS. However, only first episodes of CAPS were included in the analysis and, thus, the endpoint occurred only once. Therefore, the assumption of statistical independence is not violated.
The odds ratio (OR) of death between the groups, defined by the treatment used, was calculated by logistic regression models including adjustment variables estimated to be possible confounders in a stepwise method. The threshold probability for entering variables into the model was <0.05. The removal threshold was P > 0.10. Results are presented in terms of OR and 95% CI. An extensive set of clinical variables was evaluated to rule out possible confusion. This set of variables evaluated included: age, year of diagnosis, sex, SLE, presence and type of precipitating factors, clinical manifestations and number of organs affected, type of aPL detected, ANA and anti-ENA, platelet count, haemolytic features, presence of schistocytes and treatment with CYC. The existence of a modifier was ruled out by their statistical significance interaction with the treatment. Possible confounders were primary selected when they were statistically associated with the treatment and with survival in those that did not received the treatment. All variables with an eta value higher than 0.1 were included to build up the logistic regression model when treatment was included as a nominal variable [7, 8] . When the treatment was evaluated as a binominal variable, variables were selected when they showed an OR <0.67 or >1.5 for categorical variables or when they had an Spearman's rank correlation coefficient higher than 0.1 for continuous variables [7, 8] . Final models were build up through logistic regression models by an stepwise method [9] . All analyses were performed using SPSS version 22 with R extension when needed.
Results
Characteristics of the study cohort
The CAPS Registry cohort includes 525 episodes of CAPS accounting for 502 patients. Five hundred and two (95.6%) patients had one episode, 18 (3.4%) patients had two episodes and 5 (1.0%) patients had three episodes. Thus, 23 episodes were excluded because they were recurrences. Additionally, 31 (6.1%) episodes were excluded due to missing information regarding the outcome or the treatment prescribed. Therefore, 471 episodes of CAPS were included in the study. Patients were mainly female (68.2%) and had a mean (S.D.) age of 38.5 years (17.0). Most CAPS episodes developed in patients with primary APS (62%).
Treatments
Anticoagulation (usually intravenous heparin followed by oral anticoagulation) was the treatment prescribed most often, accounting for 403 out of 471 (85.6%) patients, followed by CS, used in 372 out of 471 (79.0%) patients, plasma exchange in 166 out of 471 (35.2%) and IVIGs in 126 patients of CAPS out of 471 (26.8%).
Triple therapy was prescribed in 189 (40.1%) CAPS patients; other combinations of treatments included in the triple therapy were prescribed in 270 (57.3%) patients, and none of these treatments in 12 patients (2.5%) (detailed treatments prescribed in Table 1) .
A comparison of clinical characteristics and laboratory features of the three different treatment groups is presented in Table 2 . Groups were generally comparable since no important differences were found between them. Patients that received triple therapy were younger than patients that received other combinations (36 vs 40 years; P = 0.046), while no difference was found in sex distribution or in their association with SLE. Additional differences were observed between groups regarding the association of a malignancy as a trigger because they were more often seen in patients that received other combinations than those that received triple therapy or none of these treatments (14.9 vs 5.1 vs 8.3%; P = 0.006). Additionally, haemolysis features (47.6 vs 30.3 vs 0%; P < 0.001), thrombocytopaenia (76.8 vs 59.5 vs 50%; P = 0.001) and schistocytes (30.8 vs 12.1 vs 0%; P < 0.001) were more often seen during the catastrophic event in those patients that received triple therapy than in the other groups. Triple positivity of aPL was observed in 26.2% among those treated with triple therapy, 18.2% among those treated with other combinations and 0% among those treated with other combinations (Table 2) . Additionally, those that received triple therapy were more often treated with CYC (34.6 vs 19.3 vs 0%; P < 0.01). All these statistically significant differences between groups were considered to build up multivariate logistic regression models.
Mortality
Overall mortality in CAPS accounted for 36.9% (174/471) of cases. Mortality rate was 28.6% (54/189) in patients who received triple therapy, 41.1% (111/270) in those who were treated with any other combination and 75% (9/12) in those who did not received any of these treatments.
Regarding the clinical characteristics of those patients who died with respect to those who survived, CAPS patients that passed away were older than those that did not (42 vs 36 years; P < 0.001). Additionally, CAPS was more often triggered by a malignancy in those that deceased (17.8 vs 6.6%; P < 0.001) and they had more often lung (76.4 vs 52.2%; P < 0.001), cardiac (56.9 vs 47.1%; P = 0.041), neurologic (66.1 vs 51.5%; P = 0.002) or renal (81.6 vs 68.4%; P = 0.002) involvement, and had higher number of organs affected (4.6 vs 3.8; P < 0.001), while those that survived more often had thrombocytopaenia (70.2% vs 60.4%; P = 0.036).
Multivariate logistic regression models showed treatment to be linked to the survival of patients with CAPS. This analysis showed the group of triple therapy to be independently statistically associated with a higher survival rate (Table 3) .
When we compared the group that received triple therapy with the one that received none of these treatments, triple therapy was found to be associated with a higher survival rate (OR = 9.7, 95% CI: 2.3, 40.6). When a comparison was performed between the group that received the triple therapy and that which received only some of these treatments, the multivariate logistic regression model showed that those patients that received triple therapy had an increased survival chance (adjusted OR = 1.7, 95% CI: 1.2, 2.6).
Thus, triple therapy led to a 46.4% (95% CI: 21.1, 71.8%) reduction of the mortality rate compared with no therapy and a 12.5% (95% CI: 3.8, 21.3%) reduction compared with any other combination. Therefore, survival could be attributed to triple therapy in 17.6% (95% CI: 5.7, 27.9%) of cases among those who received triple therapy.
SLE and primary APS group subanalysis
One hundred and forty-one patients developed CAPS associated with SLE. Overall mortality accounted for 47.5% in SLE patients and 32.1% in patients with CAPS associated with primary APS. Among the group with SLE, 54 patients (37.8%) were treated with triple therapy, 86 patients (60.1%) received other combination while only 3 (2.1%) patients were not treated with any of these treatments. Statistical analysis showed differences in the survival rate between treatment groups in patients with SLE (47.4 vs 52.6 vs 0%; P < 0.001). When patients with SLE that received triple therapy were compared with those that received other combinations the OR was 2.2 (95% CI: 1.1, 4.8; P = 0.014). Although statistical analysis showed differences (P = 0.045) between the triple therapy group survival rate (66.7%) and that in those that did not receive any treatment (0%), it was not possible to calculate the survival OR because none of the three SLE patients that received none of these treatments survived.
Overall, 277 patients developed CAPS associated with primary APS, 118 of them (42.6%) were treated with triple therapy, 153 (55.2%) were treated with other combinations and 6 (2.2%) patients with none of these treatments. Multivariable logistic regression models showed an OR of 1.5 (95% CI: 0.8, 2.7) when triple therapy was compared with other combinations and an OR of 3.1 (95% CI: 0.6, 16.0) when triple therapy was compared with the group of patients that did not receive any of these treatments.
IVIGs, plasma exchange or both
Among 189 patients that received triple therapy, 83 (43.9%) received anticoagulation, CS and plasma exchange, 62 (32.8%) received anticoagulation, CS and IVIG, and 44 (23.3%) received anticoagulation, CS, plasma exchange and IVIG. The mortality of patients that received triple therapy with IVIG and plasma exchange was 27.3% while it was 29% among those that received only triple therapy with plasma exchange or IVIGs (27.4% among those that received IVIG without plasma exchange, and 30.1% among those that received plasma exchange without IVIG). The multivariate logistic regression model did not find any differences in the survival rate between the three groups of patients (P = 0.913). No differences were found between those that received both treatments and those that received only one of them (OR = 1.1, 95% CI: 0.5, 2.3; P = 0.83).
Haemolysis, thrombocytopaenia and schistocytes subgropus analysis
Among the subgroup of patients that had thrombocytopaenia and the subgroup that had haemolysis, triple therapy continued to show a clear benefit over other combinations [OR (95% CI) = 1.7 (1.1, 2.9) and 2.4 (1.1, 4.9), respectively]. However, it was not possible to show this benefit in the subgroup of patients with schistocytes (OR = 1.9, 95% CI: 0.6, 6.3). Plasma exchange did not seem to add a value when face to face comparison was undertaken in the subgroups with thrombocytopaenia, haemolysis and schistocytes [OR (95% CI) = 1.1 (0.7, 1.8), 1.1 (0.5, 2.2) and 0.8 (0.2, 2.5), respectively]. These findings did not differ when multivariable regression analysis was performed adjusting by possible confounders.
Discussion
In the present study triple therapy was associated with a higher survival rate in patients with CAPS. The mortality rate of patients who received triple therapy was 28% whereas in patients that did not receive any treatment it was 75%. In 1998, Asherson et al. [2] proposed the combination of anticoagulation, CS and plasma exchange or IVIG as the best therapeutic approach for CAPS based on the hypothetical pathogenic mechanisms of the syndrome. Current knowledge states that CAPS is caused by a thrombotic storm that leads to a cytokine storm [10] . Based on this pathological model, anticoagulation would stop the thrombotic storm while CS would hamper cytokine excess, and plasma exchange and IVIG remove from the plasma circulating proinflammatory cytokines and aPLs [11] .
The mortality rate found in this study represents an important reduction compared with previous reports [2, 4, 5] . Since the first series of Asherson et al. [2, 4] , the mortality linked to CAPS was up to 50%. This high mortality rate was confirmed in succeeding series [5] . In a more recent study, the mortality rate decreased over time from 53% in patients diagnosed before 2001 to 33% in those diagnosed between 2001 and 2005 [5] . The most important and clinically relevant difference between the two periods was the higher use of the combination of anticoagulation plus CS plus plasma exchange and/or IVIG in the second period. Therefore, the authors attributed the decrease in CAPS mortality ratio to this increasing use of the so-called 'triple therapy' after 2001 [5] . However, this hypothesis could not be proved at that point. The current study shows a statistical association between the triple therapy and the decrease of mortality rate of patients with CAPS when compared with other combinations or with none of the treatments included in the triple therapy.
Interestingly, no differences in the mortality rate were found between the three triple therapy groups: patients that received plasma exchange and IVIG, patients that received IVIG without plasma exchange and those who received plasma exchange without IVIG. This finding has an important practical implication since the plasma exchange procedure is not available in all centres, whereas IVIGs are available in many hospitals and can be administered without delay. Further, plasma exchange might be difficult to perform in paediatric or pregnant patients, while administration of IVIG is easier and safer [12] . Interestingly, it seems that there is no need to administer IVIG and plasma exchange together since it seems not to provide benefit over one of these treatments without the other. This is also true for the subgroup of patients with thrombocytopaenia, haemolysis or schistocytes.
The strength of our study comes from the large sample size and the possibility to adjust for several confounders. Further, the multicentre nature of the study and its hard endpoint, that is, death, increases the external validity of our findings.
There are limitations in the current study since data come from published reports and cases reported to the CAPS Registry coordinators. Therefore, some information might be incomplete or inaccurate, and results might be affected by publication bias. In this sense, is was not possible to analyse the timing of treatements or the dose used since these data are not available in the cases reported and we do not know their impact on patients' outcomes. Moreover, due to the observational nature of our study, we cannot exclude possible residual confounding. However, although an observational study is not the ideal approach to evaluate the effect of treatment following evidencebased medicine, the rarity of CAPS precludes driving any prospective trial in these patients.
In conclusion, the triple therapy is associated with a reduction of the risk of death among patients with CAPS of 46%. Further, no differences have been found between the use of plasma exchange and/or IVIG in patients with CAPS. 
